A data frame used to illustrate the cg package. It has a One Factor / One-Way / Unpaired Samples layout. It also contains left-censored values of varying degree in each of the six groups.
A 8-by-6 data frame with up to 8 numeric observations per group from an experiment on the following 6 groups.
phosphate buffered saline control group
1 mg/kg dose
3 mg/kg dose
10 mg/kg dose
30 mg/kg dose
phosphate buffered saline control group of wild-type mice
The first five groups have transgenic (Tg197) mice subjects, a well established model to induce arthritis. The sixth group are "wild-type" mice that did not have arthritis induced. The various doses of the inner four groups are administrations of golimumab, a monoclonal antibody therapy.
The individual group values are of mode character, since some of them
are represented as left-censored values such as
that two of the groups have less than 8 observations, and the
corresponding cells in the data frame actually contain empty quote
gmcsfcens data set that comes with the cg package
groupcolumns format. Each column represents a group, and
the observations in that group's column are the individual response
values. As described above, they are character valued potentially
The 6 groups are regarded as levels of one factor in the
fit, and other methods in
the cg package.
Alternative formats of this data set is contained in
gmcsfcens.listfmt. See that help file for details,
including how such formats would be read and
prepared by cg.
GM-CSF stands for Granulocyte macrophage colony stimulating factor, a type of cytokine that is important in the growth of white blood cells. It is one of the outcomes measured in the experiment described in the references section below. Therapeutic inhibition of it may be beneficial in cases where too many white blood cells are produced, such as arthritis. In other situations where white blood cell counts are low, stimulation of it is desired. In the referenced study below, GM-CSF is evaluated in the context of inflammation.
Contact email@example.com for bug reports, questions, concerns, and comments.
Shealy, D., Cai, A., Staquet, K., Baker, A., Lacy, E., Johns, L., Vafa, O., Gunn, G., Tam, S., Sague, S., Wang, D., Brigham-Burke, M., Dalmonte, P., Emmell, E., Pikounis, B., Bugelski, P., Zhou, H., Scallon, B., Giles-Komar, J. (2010). "Characterization of Golimumab (CNTO148), a human monoclonal antibody specific for human tumor necrosis factor ", mAbs, Volume 2, Issue 4, 428-439.